# Johnson & Johnson announces new Phase 2 nipocalimab study data in Sjögren's disease that reveal insights on importance of symptom improvements most valued by patients

- Source: PR Newswire General Business
- Published: 2026-11-07T15:03:00+00:00
- Category: Business
- Original: https://www.prnewswire.com/news-releases/johnson--johnson-announces-new-phase-2-nipocalimab-study-data-in-sjogrens-disease-that-reveal-insights-on-importance-of-symptom-improvements-most-valued-by-patients-302932516.html
- Canonical: https://groundlevelnews.com/story/johnson-johnson-announces-new-phase-2-nipocalimab-study-data-in-sj-gre-5bce5e/

New patient experience dataa to be presented at ACR 2026 show mouth dryness was reported as the most important symptom to improve, followed by eye dryness, fatigue and joint pain Patient insights complement Phase 2 study results demonstrating a 50% increase in saliva productionb in more...

_Ground Level News shows a short summary only; the full article and all rights belong to PR Newswire General Business._